News for BCEL Stock

Immunome to Acquire Antibody-Related Assets and Materials from Atreca Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross Atreca Reports Second Quarter 2023 Financial Results and Announces Corporate Restructuring Atreca Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors during Oral Abstract Session at the ASCO 2023 Annual Meeting Atreca Reports First Quarter 2023 Financial Results and Recent Corporate Developments Atreca Announces Oral Presentation of ATRC-101 Phase 1b Study Data at ASCO 2023 Annual Meeting Atreca to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference Atreca Reports Fourth Quarter and Full-Year 2022 Financial Results and ATRC-101 Data Update Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023 Atreca to Participate at Cowen’s 43rd Annual Health Care Conference Atreca and Xencor to Develop T Cell Engaging Bispecific Antibody Directed Against Novel Solid Tumor Target Atreca Appoints Philippe Bishop, MD as Chief Medical Officer Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update Atreca to Present at Upcoming Investor Conferences Atreca Announces Poster Presentations at Society for Immunotherapy of Cancer (SITC) Annual Meeting Atreca to Present at Upcoming Investor Conferences Atreca Reports Second Quarter 2022 Financial Results and Recent Corporate Developments Atreca to Present at Upcoming Investor Conferences Cellino Announces Appointment of Abhijit Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Chief Business Officer Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer Atreca Announces Corporate Reorganization to Extend Cash Runway Atreca to Present at Upcoming Investor Conferences Atreca Reports First Quarter 2022 Financial Results and Recent Corporate Developments Atreca Announces Publication in PNAS: “Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101” Atreca to Present at Upcoming Virtual Investor Conferences Atreca Announces Expansion of Preclinical Pipeline Atreca to Host Virtual R&D Day on Tuesday, April 5, 2022 Atreca to Participate in Cowen 42nd Annual Healthcare Conference Atreca Reports Fourth Quarter and Full-Year 2021 Financial Results and ATRC-101 Data Update Atreca to Report Fourth Quarter 2021 Results and Host Year-End Conference Call on March 3, 2022 Atreca to Present Anti-SARS-CoV-2 Antibody Discoveries at Keystone Symposia Conference: Antibodies as Drugs Atreca to Present at Upcoming Virtual Investor Conferences Atreca Reports Third Quarter 2021 Financial Results and Recent Corporate Developments Atreca Enters into Licensing Agreement with Bill & Melinda Gates Medical Research Institute to Develop a Monoclonal Antibody for the Prevention of Malaria    Atreca Announces Poster Presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Atreca to Present at Upcoming Virtual Investor Conferences Atreca Reports Second Quarter 2021 Financial Results and Recent Corporate Developments Atreca to Present at Upcoming Virtual Investor Conferences Atreca Presents Initial Clinical Data from Phase 1b Trial of ATRC-101 in Select Advanced Solid Tumors Atreca to Host Webcast Presentation of Initial Clinical Data from Phase 1b Trial of ATRC-101 Atreca Announces Appointment of Dr. Stacey Ma and Stephen R. Brady to its Board of Directors Atreca to Present at Upcoming Virtual Investor Conferences Atreca Reports First Quarter 2021 Financial Results and Recent Corporate Developments Atreca to Present at Upcoming Virtual Investor Conferences Atreca Announces Poster Presentation at the Virtual American Association for Cancer Research (AACR) Annual Meeting Atreca Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Developments Atreca to Participate at Upcoming Virtual Investor Conferences Atreca Reports Third Quarter 2020 Financial Results and Recent Corporate Developments Atreca to Present at Upcoming Virtual Investor Conferences Atreca Announces Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting Atreca to Present at Two Upcoming Virtual Healthcare Conferences Atreca, Inc. Announces Proposed Underwritten Public Offering of Class A Common Stock Atreca Announces Webinar to Present ATRC-101 Preclinical Data Update on Monday, June 15, 2020 Atreca Announces Participation in the 2020 RBC Capital Markets Virtual Global Healthcare Conference Atreca, Inc. Announces Pricing of Underwritten Public Offering of Common Stock Atreca and Xencor Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies Atreca Reports First Quarter 2020 Financial Results and Recent Corporate Developments